Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat + dapagliflozin to prevent heart failure in high‑risk type 2 diabetes
jRCT2031240738Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM), heart failure (HF), hypertension (HTN) and 1 more comparing Baxdrostat + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Primary composite endpoint of heart failure events and cardiovascular death. Started Mar 2025; status: recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on jRCT2031240738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240738.